Geoffrey Maltzahn - Kaleido Biosciences President Co-Founder
KLDODelisted Stock | USD 0.01 0.00 0.00% |
President
Mr. Geoffrey von Maltzahn is the President, CoFounder of the Company. He is a leading innovator and entrepreneur in the microbiome and biotechnology and is a cofounder of companies that have achieved over 3 billion in private and public market capitalization. He is a partner at Flagship Pioneering and has cofounded multiple biotech companies including Seres Therapeutics, Indigo Agriculture, Axcella Health, and Sienna Biopharmaceuticals . He recently served as the President of Indigo, where he led the creation of the worlds largest plant microbiome database and development of the companys first commercial products. Von Maltzahn is an inventor on more than 100 patents and patent applications in biotech, nutrition and microbiomebased technologies and was recognized with numerous awards, including the prestigious LemelsonMIT student prize, given to the most innovative student at MIT. Von Maltzahns innovations have been profiled by the Economist, CNN, Fortune, Scientific American, Popular Science and others. He received his PhD from MIT in the HarvardMIT Division of Health Sciences and Technology.
Professional Marks | Ph.D |
Phone | 617 674 9000 |
Web | https://kaleido.com |
Kaleido Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.9993) % which means that it has lost $0.9993 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.8057) %, meaning that it created substantial loss on money invested by shareholders. Kaleido Biosciences' management efficiency ratios could be used to measure how well Kaleido Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 5.55 M in liabilities with Debt to Equity (D/E) ratio of 2.05, implying the company greatly relies on financing operations through barrowing. Kaleido Biosciences has a current ratio of 1.39, which is within standard range for the sector. Debt can assist Kaleido Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Kaleido Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kaleido Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kaleido to invest in growth at high rates of return. When we think about Kaleido Biosciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | PRESIDENT Age | ||
Thomas Corr | Tootsie Roll Industries | 69 | |
Steven Burdette | Haverty Furniture Companies | 62 | |
Richard Hare | Haverty Furniture Companies | 57 | |
Kathleen DalyJennings | Haverty Furniture Companies | 53 | |
Ann Zaccaria | Bassett Furniture Industries | N/A | |
Rawson Haverty | Haverty Furniture Companies | 67 | |
Chris Kelly | LGI Homes | N/A | |
John Daniel | Bassett Furniture Industries | 56 | |
David Baker | Bassett Furniture Industries | 63 | |
Allan DeNiro | Haverty Furniture Companies | 64 | |
Gary Knisely | Hanover Foods | 75 | |
Thomas Curran | Haverty Furniture Companies | 60 | |
Peitro Giraffa | Hanover Foods | 62 | |
Andrew Mathias | SL Green Realty | 50 | |
John Majors | Tootsie Roll Industries | 55 | |
Janet Taylor | Haverty Furniture Companies | 62 | |
Moina Banerjee | JBG SMITH Properties | 36 | |
Parimala Rao | SL Green Realty | N/A | |
Helen Bautista | Haverty Furniture Companies | 57 | |
Rachel Eaton | LGI Homes | 42 | |
David Paul | JBG SMITH Properties | 61 |
Management Performance
Return On Equity | -5.81 | ||||
Return On Asset | -1.0 |
Kaleido Biosciences Leadership Team
Elected by the shareholders, the Kaleido Biosciences' board of directors comprises two types of representatives: Kaleido Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kaleido. The board's role is to monitor Kaleido Biosciences' management team and ensure that shareholders' interests are well served. Kaleido Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kaleido Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Geoffrey Maltzahn, President Co-Founder | ||
Jeremy Buzzard, Senior Vice President - Corporate Development | ||
Johannes Vlieg, Chief Scientific Officer | ||
Grady Burnett, Director | ||
Mark Wingertzahn, VP Devel | ||
Bonnie Bassler, Director | ||
Jeffery Moore, Senior Vice President - Finance & Administration | ||
Clare Fisher, Chief Business Officer | ||
LLM JD, Chief Advisor | ||
Jerald Korn, General Counsel, Corporate Secretary | ||
Mike Bonney, Chairman of the Board, CEO | ||
John Sculley, Director | ||
Ruth ThieroffEkerdt, Chief Medical Officer | ||
Theo MelasKyriazi, Independent Director | ||
Kimberly Hocknell, VP Operations |
Kaleido Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Kaleido Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -5.81 | ||||
Return On Asset | -1.0 | ||||
Operating Margin | (79.28) % | ||||
Current Valuation | (16.73 M) | ||||
Shares Outstanding | 42.62 M | ||||
Shares Owned By Insiders | 0.73 % | ||||
Shares Owned By Institutions | 0.36 % | ||||
Number Of Shares Shorted | 2.34 M | ||||
Price To Earning | (1.45) X | ||||
Price To Book | 0 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kaleido Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kaleido Biosciences' short interest history, or implied volatility extrapolated from Kaleido Biosciences options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Kaleido Biosciences information on this page should be used as a complementary analysis to other Kaleido Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Kaleido Pink Sheet
If you are still planning to invest in Kaleido Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kaleido Biosciences' history and understand the potential risks before investing.
CEOs Directory Screen CEOs from public companies around the world | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |